Protocol Number: REDEEM-AVO105948, Sponsor: GlaxoSmithKline
 
  Eligibility

Criteria for participation:
  • Must be male >50 and <80 years of age
  • Have biopsy proven, low-risk, localized prostate cancer and active in expectant management ?1 year.
  • Gleason score <6
  • Clinical stage T1c-T2a
  • Serum PSA <10ng/mL
  • A life expectancy greater than five years.
  • Able to swallow and retain oral medication
  • Able and willing to participate in the full three years of the study
  • No previous treatment for prostate cancer with any of the following,
    • Radiotherapy (external beam or brachytherapy) Chemotherapy
    • Hormonal therapy
    • Oral glucocorticoids
    • GnRH analogues


Duration of Study
Study period will be a duration of three years, in which you will either receive the medication or placebo (sugar pill) in pill form once daily.

Clinical Research Coordinators:
Patricia Edwards, RN (336) 274-1114 ext. 5322
Karen Michael, RN (336) 274-1114 ext. 5328
E-mail address: research@allianceurology.com



Printable View